Longevity & AgingArticolo di ricercaAccesso aperto

GDF-15 stress marker predicts heart disease and fatty liver risk in 29,697 UK adults

In 29,697 UK Biobank adults, higher blood GDF-15 tracked with later heart disease and fatty liver, but it added only modest predictive value to existing scores.

venerdì 20 novembre 2026 1 visualizzazione
Pubblicato in Cardiovasc Diabetol
Glowing GDF-15 protein molecule floating in blood plasma beside a stylized heart, kidney and liver connected by light threads

Riepilogo

GDF-15 is a stress-response protein that rises with inflammation, oxidative stress and cellular aging. This UK Biobank cohort study measured it in 29,697 adults aged about 56 with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 and followed them for about 16 years. Higher GDF-15 was linked to later atherosclerotic cardiovascular disease (ASCVD; fully adjusted HR 1.25 per unit), fatty liver disease (MASLD; HR 1.62) and having both (HR 1.62). It also predicted movement between the two diseases in both directions. Adding GDF-15 to established risk scores (PREVENT, SCORE2, FLI, FIB-4, APRI) gave modest gains, mainly for ASCVD. This is observational, so it shows association and prediction, not that GDF-15 causes disease or that lowering it helps. Only 456 MASLD cases occurred, so the liver estimates are less certain.

0:00--:--

Riepilogo Dettagliato

GDF-15 is a stress-responsive protein in the TGF-beta family. Levels rise with inflammation, oxidative stress, kidney dysfunction and cellular aging, so it may capture shared biology across the heart, kidneys, liver and metabolism. This study asked whether measuring it helps predict disease in people with early-stage cardiovascular-kidney-metabolic (CKM) syndrome, before clinical cardiovascular disease.

Researchers analyzed 29,697 UK Biobank participants in CKM stages 0-3 (mean age 56, 57% female). Plasma GDF-15 was measured with the Olink proximity extension assay. Over a median of about 16 years, 2,786 people developed ASCVD (coronary disease or ischaemic stroke) and 456 developed MASLD. Outcomes were identified from ICD-10 codes in health records. Fine-Gray competing-risk models, multi-state Markov models, SHAP importance analysis and standard discrimination and reclassification metrics were used.

Higher GDF-15 rose stepwise with CKM stage and was most strongly tied to kidney markers (cystatin C, creatinine), then insulin resistance indices. After full adjustment, each 1-unit rise (log2 scale) was associated with higher risk of ASCVD (HR 1.25, 95% CI 1.15-1.36), MASLD (HR 1.62, 1.41-1.86) and both together (HR 1.62). Unadjusted hazard ratios were larger (ASCVD 2.04), so much of the raw signal overlaps with age, kidney function and metabolic status. Subgroup results showed no significant heterogeneity. In multi-state models, higher GDF-15 was associated with progression from ASCVD to MASLD (HR 1.55, 1.03-2.34) and from MASLD to ASCVD (HR 1.59, 1.01-2.50), though these confidence intervals are wide and borderline. Among people in the top 10% of GDF-15, 10-year cumulative incidence was 15.75% for ASCVD and 2.03% for MASLD.

Adding GDF-15 to PREVENT, SCORE2, FLI, FIB-4 and APRI improved discrimination, reclassification and prediction error only modestly, mostly for ASCVD. In some comparisons it outperformed other markers such as lipoprotein(a), troponin I, NT-proBNP, apolipoprotein ratios and inflammation or insulin resistance indices.

Caveats: this is observational and cannot show that GDF-15 drives disease. This work does not test any lowering of GDF-15, and no function or lifespan outcome was assessed. The data come from a largely White, healthier-than-average UK volunteer cohort, with a single baseline measurement. MASLD was captured by diagnostic codes, which likely miss many cases. CKM stage 3 was defined by predicted risk, and 81% of participants were stage 2. GDF-15 is a marker of general stress, so it is not specific to any one disease. Validation in other populations and cost-effectiveness data are needed before clinical use.

Risultati Principali

  • Across 29,697 adults (CKM stages 0-3), higher GDF-15 rose with CKM stage and tracked most strongly with kidney markers.
  • Fully adjusted, each 1-unit GDF-15 increase carried HR 1.25 for ASCVD and 1.62 for MASLD; unadjusted ASCVD HR was 2.04.
  • Top-decile GDF-15 had 15.75% 10-year ASCVD incidence; multi-state HRs for ASCVD-MASLD transitions were borderline (about 1.55-1.59).
  • Adding GDF-15 to PREVENT, SCORE2, FLI, FIB-4 and APRI gave only modest gains, mainly for ASCVD.

Metodologia

Prospective observational analysis of UK Biobank participants with Olink plasma proteomics, about 16 years of follow-up, and 2,786 ASCVD and 456 MASLD events from record-linked ICD-10 codes. Fine-Gray competing-risk models adjusted for 4 covariate sets, multi-state Markov models, SHAP and likelihood-ratio importance, and AUC, Brier, IDI and NRI comparisons against established scores were used. Sensitivity analyses included haemorrhagic stroke, SCORE2-defined stage 3 and Cox models.

Limitazioni dello Studio

Observational design means association only; confounding by kidney function, age and unmeasured factors remains possible, and a single baseline measurement was used. The cohort is mostly White and healthier than the general population, MASLD was identified through diagnostic codes with only 456 cases, and the multi-state estimates are imprecise. External validation, calibration and clinical-utility testing are not shown.

Ti è piaciuto questo riepilogo?

Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.

Inserisci la tua email per iscriverti: